Citadel Advisors’s Blueprint Medicines BPMC Stock Holding History

Citadel Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-72,300	Closed	-$9.27M	–	12800
2025 Q2	$9.27M	Sell	72,300 -11,600	-14%	-$1.2M	﹤0.01%	3139
2025 Q1	$7.43M	Sell	83,900 -28,500	-25%	-$2.78M	﹤0.01%	3284
2024 Q4	$9.8M	Buy	112,400 +24,500	+28%	+$2.24M	﹤0.01%	3012
2024 Q3	$8.13M	Buy	87,900 +2,800	+3%	+$278K	﹤0.01%	3225
2024 Q2	$9.17M	Buy	85,100 +17,200	+25%	+$1.72M	﹤0.01%	2871
2024 Q1	$6.44M	Buy	67,900 +2,900	+4%	+$249K	﹤0.01%	3567
2023 Q4	$6M	Buy	65,000 +13,000	+25%	+$842K	﹤0.01%	3545
2023 Q3	$2.61M	Buy	52,000 +10,300	+25%	+$550K	﹤0.01%	4739
2023 Q2	$2.64M	Buy	41,700 +13,600	+48%	+$739K	﹤0.01%	4679
2023 Q1	$1.26M	Sell	28,100 -14,800	-34%	-$667K	﹤0.01%	6288
2022 Q4	$1.88M	Buy	42,900 +19,000	+79%	+$911K	﹤0.01%	5605
2022 Q3	$1.57M	Sell	23,900 -10,000	-29%	-$642K	﹤0.01%	6051
2022 Q2	$1.71M	Buy	33,900 +21,600	+176%	+$1.27M	﹤0.01%	5860
2022 Q1	$786K	Buy	12,300 +9,100	+284%	+$653K	﹤0.01%	8256
2021 Q4	$343K	Sell	3,200 -400	-11%	-$41.8K	﹤0.01%	10613
2021 Q3	$370K	Sell	3,600 -2,000	-36%	-$186K	﹤0.01%	10576
2021 Q2	$493K	Sell	5,600 -1,700	-23%	-$156K	﹤0.01%	10094
2021 Q1	$710K	Sell	7,300 -1,700	-19%	-$170K	﹤0.01%	8913
2020 Q4	$1.01M	Buy	9,000 +4,300	+91%	+$453K	﹤0.01%	6781
2020 Q3	$436K	Sell	4,700 -7,500	-61%	-$578K	﹤0.01%	7525
2020 Q2	$952K	Sell	12,200 -1,700	-12%	-$115K	﹤0.01%	5919
2020 Q1	$813K	Sell	13,900 -21,600	-61%	-$1.39M	﹤0.01%	5681
2019 Q4	$2.84M	Buy	35,500 +16,600	+88%	+$1.24M	﹤0.01%	3857
2019 Q3	$1.39M	Buy	18,900 +10,700	+130%	+$925K	﹤0.01%	5056
2019 Q2	$774K	Buy	8,200 +4,000	+95%	+$330K	﹤0.01%	6116
2019 Q1	$336K	Sell	4,200 -7,500	-64%	-$554K	﹤0.01%	7448
2018 Q4	$631K	Sell	11,700 -7,500	-39%	-$456K	﹤0.01%	6040
2018 Q3	$1.5M	Sell	19,200 -13,100	-41%	-$910K	﹤0.01%	4876
2018 Q2	$2.05M	Buy	32,300 +400	+1%	+$31.8K	﹤0.01%	4074
2018 Q1	$2.92M	Sell	31,900 -20,200	-39%	-$1.74M	﹤0.01%	3177
2017 Q4	$3.93M	Buy	52,100 +36,900	+243%	+$2.6M	﹤0.01%	2758
2017 Q3	$1.06M	Buy	15,200 +1,300	+9%	+$69.5K	﹤0.01%	4245
2017 Q2	$704K	Buy	13,900 +3,600	+35%	+$153K	﹤0.01%	4623
2017 Q1	$412K	Buy	+10,300	New	+$369K	﹤0.01%	5349
2016 Q1	–	Sell	-5,100	Closed	-$134K	–	6818
2015 Q4	$134K	Buy	5,100 +1,800	+55%	+$40.5K	﹤0.01%	6349
2015 Q3	$70K	Buy	+3,300	New	+$91.3K	﹤0.01%	7299

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's BPMC Position: Q3 2025 in Review

Citadel Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 25,094 shares — an estimated $3.22M sold.

Citadel Advisors first reported a position in BPMC in Q2 2015 and held it in 36 quarters. The position peaked at $56.7M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Citadel Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 25,094 Blueprint Medicines shares in Q3 2025, an estimated $3.22M.
Citadel Advisors first reported a position in Blueprint Medicines in Q2 2015 and held it in 36 quarters.
Citadel Advisors's Blueprint Medicines position peaked at $56.7M in Q4 2024.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.